Table 1.
Clinical characteristics of ramosetron responders and non-responders
| Total n=42 | Non-responders n=16 | Responders n=26 | p | |
|---|---|---|---|---|
| Age mean (SD) | 42 (16) | 43 (15) | 42 (17) | 0.80 |
| Gender men (%) | 27 (67.5) | 11 (68.8) | 16 (61.5) | *0.64 |
| Concomitant medicationa | 20 | 8 | 12 | 1.0 |
| Calcium Polycarbophil | 12 | 5 | 7 | 1.0 |
| Mepenzolate bromide | 4 | 2 | 2 | 0.63 |
| Bifidobacterium | 3 | 0 | 3 | 0.28 |
| Antidepressant | 3 | 2 | 1 | 0.55 |
| Ramosetron dose | ||||
| 5μg | 17 | 5 | 12 | |
| 5μg to 2.5μg | 14 | 1 | 13 | |
| Discontinuation | 11 | 10 | 1 | |
| Adverse event | ||||
| Abdominal discomfort | 9 | 7 | 2 | |
| Constipation | 8 | 1 | 7 | |
| Headache | 1 | 1 | 0 |
a
Concomitant medication for IBS symptoms
*
p Values, by unpaired t test or by chi square analyses